Pyridam Farma Tbk (PYFA) - Net Assets

Latest as of September 2025: Rp732.89 Billion IDR ≈ $42.94 Million USD

Based on the latest financial reports, Pyridam Farma Tbk (PYFA) has net assets worth Rp732.89 Billion IDR (≈ $42.94 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp6.92 Trillion ≈ $405.45 Million USD) and total liabilities (Rp6.19 Trillion ≈ $362.51 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PYFA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets Rp732.89 Billion
% of Total Assets 10.59%
Annual Growth Rate 13.16%
5-Year Change 559.48%
10-Year Change 927.0%
Growth Volatility 49.62

Pyridam Farma Tbk - Net Assets Trend (2001–2024)

This chart illustrates how Pyridam Farma Tbk's net assets have evolved over time, based on quarterly financial data. Also explore how large is Pyridam Farma Tbk's balance sheet for the complete picture of this company's asset base.

Annual Net Assets for Pyridam Farma Tbk (2001–2024)

The table below shows the annual net assets of Pyridam Farma Tbk from 2001 to 2024. For live valuation and market cap data, see PYFA company net worth.

Year Net Assets Change
2024-12-31 Rp1.04 Trillion
≈ $60.91 Million		 +191.14%
2023-12-31 Rp357.06 Billion
≈ $20.92 Million		 -19.28%
2022-12-31 Rp442.36 Billion
≈ $25.92 Million		 +164.73%
2021-12-31 Rp167.10 Billion
≈ $9.79 Million		 +6.01%
2020-12-31 Rp157.63 Billion
≈ $9.24 Million		 +26.38%
2019-12-31 Rp124.73 Billion
≈ $7.31 Million		 +4.88%
2018-12-31 Rp118.93 Billion
≈ $6.97 Million		 +9.25%
2017-12-31 Rp108.86 Billion
≈ $6.38 Million		 +3.17%
2016-12-31 Rp105.51 Billion
≈ $6.18 Million		 +4.23%
2015-12-31 Rp101.22 Billion
≈ $5.93 Million		 +4.25%
2014-12-31 Rp97.10 Billion
≈ $5.69 Million		 +3.40%
2013-12-31 Rp93.90 Billion
≈ $5.50 Million		 +7.06%
2012-12-31 Rp87.71 Billion
≈ $5.14 Million		 +6.44%
2011-12-31 Rp82.40 Billion
≈ $4.83 Million		 +6.70%
2010-12-31 Rp77.23 Billion
≈ $4.53 Million		 +5.75%
2009-12-31 Rp73.03 Billion
≈ $4.28 Million		 +5.45%
2008-12-31 Rp69.25 Billion
≈ $4.06 Million		 +3.45%
2007-12-31 Rp66.94 Billion
≈ $3.92 Million		 +2.67%
2006-12-31 Rp65.20 Billion
≈ $3.82 Million		 +2.72%
2005-12-31 Rp63.47 Billion
≈ $3.72 Million		 +2.14%
2004-12-31 Rp62.14 Billion
≈ $3.64 Million		 +2.36%
2003-12-31 Rp60.71 Billion
≈ $3.56 Million		 +1.03%
2002-12-31 Rp60.09 Billion
≈ $3.52 Million		 -0.71%
2001-12-31 Rp60.52 Billion
≈ $3.55 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Pyridam Farma Tbk's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 572.8% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock Rp1.12 Trillion 108.09%
Other Comprehensive Income Rp-41.39 Billion -3.98%
Other Components Rp2.07 Billion 0.20%
Total Equity Rp1.04 Trillion 100.00%

Pyridam Farma Tbk Competitors by Market Cap

The table below lists competitors of Pyridam Farma Tbk ranked by their market capitalization.

Company Market Cap
Hengyuan Refining Company Bhd
KLSE:4324
 $198.85 Million
MacroGenics Inc
NASDAQ:MGNX
 $198.94 Million
Gwangjushinseg
KO:037710
 $199.00 Million
Anika Therapeutics Inc
NASDAQ:ANIK
 $199.00 Million
PAMT CORP
NASDAQ:PAMT
 $198.76 Million
Siward Crystal Technology Co Ltd
TW:2484
 $198.65 Million
Asia Sermkij Leasing Public Company Limited
BK:ASK
 $198.53 Million
NIBEC Co. Ltd
KQ:138610
 $198.48 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Pyridam Farma Tbk's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 356,833,920,095 to 1,039,539,307,000, a change of 682,705,386,905 (191.3%).
  • Net loss of 330,246,642,000 reduced equity.
  • Dividend payments of 31,630,163,000 reduced retained earnings.
  • Share repurchases of 1,070,161,504,800 reduced equity.
  • New share issuances of 1,070,161,504,800 increased equity.
  • Other comprehensive income decreased equity by 57,209,511,628.
  • Other factors increased equity by 1,101,791,703,533.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income Rp-330.25 Billion -31.77%
Dividends Paid Rp31.63 Billion -3.04%
Share Repurchases Rp1.07 Trillion -102.95%
Share Issuances Rp1.07 Trillion +102.95%
Other Comprehensive Income Rp-57.21 Billion -5.5%
Other Changes Rp1.10 Trillion +105.99%
Total Change Rp- 191.32%

Book Value vs Market Value Analysis

This analysis compares Pyridam Farma Tbk's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.47x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 12.73x to 2.47x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2005-12-31 Rp23.72 Rp302.00 x
2006-12-31 Rp24.37 Rp302.00 x
2007-12-31 Rp25.02 Rp302.00 x
2008-12-31 Rp25.89 Rp302.00 x
2009-12-31 Rp27.30 Rp302.00 x
2010-12-31 Rp28.86 Rp302.00 x
2011-12-31 Rp30.80 Rp302.00 x
2012-12-31 Rp32.78 Rp302.00 x
2013-12-31 Rp35.10 Rp302.00 x
2014-12-31 Rp36.29 Rp302.00 x
2015-12-31 Rp37.83 Rp302.00 x
2016-12-31 Rp39.44 Rp302.00 x
2017-12-31 Rp203.44 Rp302.00 x
2018-12-31 Rp222.26 Rp302.00 x
2019-12-31 Rp233.10 Rp302.00 x
2020-12-31 Rp63.25 Rp302.00 x
2021-12-31 Rp312.29 Rp302.00 x
2022-12-31 Rp826.28 Rp302.00 x
2023-12-31 Rp143.18 Rp302.00 x
2024-12-31 Rp122.47 Rp302.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Pyridam Farma Tbk utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -31.77%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -17.19%
  • • Asset Turnover: 0.33x
  • • Equity Multiplier: 5.59x
  • Recent ROE (-31.77%) is below the historical average (4.49%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 7.76% 16.06% 0.38x 1.27x Rp-1.36 Billion
2002 0.73% 1.77% 0.35x 1.16x Rp-5.57 Billion
2003 1.02% 2.27% 0.40x 1.12x Rp-5.45 Billion
2004 2.30% 4.21% 0.48x 1.13x Rp-4.78 Billion
2005 2.09% 3.35% 0.52x 1.21x Rp-5.02 Billion
2006 2.65% 2.82% 0.74x 1.27x Rp-4.79 Billion
2007 2.60% 2.01% 0.91x 1.42x Rp-4.95 Billion
2008 3.33% 1.93% 1.21x 1.42x Rp-4.62 Billion
2009 5.17% 2.86% 1.32x 1.37x Rp-3.53 Billion
2010 5.44% 2.98% 1.40x 1.30x Rp-3.52 Billion
2011 6.28% 3.42% 1.28x 1.43x Rp-3.07 Billion
2012 6.05% 3.00% 1.30x 1.55x Rp-3.46 Billion
2013 6.60% 3.22% 1.10x 1.86x Rp-3.19 Billion
2014 2.74% 1.20% 1.29x 1.78x Rp-7.05 Billion
2015 3.05% 1.42% 1.36x 1.58x Rp-7.04 Billion
2016 4.88% 2.37% 1.30x 1.58x Rp-5.40 Billion
2017 6.55% 3.20% 1.40x 1.47x Rp-3.76 Billion
2018 7.10% 3.37% 1.34x 1.57x Rp-3.45 Billion
2019 7.49% 3.78% 1.30x 1.53x Rp-3.13 Billion
2020 14.02% 7.97% 1.21x 1.45x Rp6.34 Billion
2021 3.28% 0.87% 0.78x 4.82x Rp-11.23 Billion
2022 62.25% 38.47% 0.47x 3.44x Rp231.03 Billion
2023 -23.88% -12.14% 0.46x 4.26x Rp-120.90 Billion
2024 -31.77% -17.19% 0.33x 5.59x Rp-434.20 Billion

Industry Comparison

This section compares Pyridam Farma Tbk's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $746,339,912,481
  • Average return on equity (ROE) among peers: 50.29%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Pyridam Farma Tbk (PYFA) Rp732.89 Billion 7.76% 8.44x $198.84 Million
Darya-Varia Laboratoria Tbk (DVLA) $507.85 Billion 13.94% 0.26x $105.33 Million
Indofarma Tbk (INAF) $298.72 Billion 0.71% 1.44x $22.88 Million
Merck Tbk (MERK) $518.28 Billion 224.46% 1.44x $110.25 Million
Phapros Tbk PT (PEHA) $740.98 Billion 1.49% 1.48x $14.67 Million
Sido Muncul PT (SIDO) $1.30 Trillion 29.70% 0.65x $862.39 Million
Tempo Scan Pacific Tbk (TSPC) $1.11 Trillion 31.40% 0.29x $644.79 Million

About Pyridam Farma Tbk

JK:PYFA Indonesia Drug Manufacturers - Specialty & Generic
Market Cap
$198.84 Million
Rp3.39 Trillion IDR
Market Cap Rank
#16552 Global
#244 in Indonesia
Share Price
Rp302.00
Change (1 day)
-6.79%
52-Week Range
Rp200.00 - Rp645.00
All Time High
Rp1480.00
Categories
Companies in Indonesia Drug Manufacturers - Specialty & Generic
About

PT Pyridam Farma Tbk engages in the development, production, and trading of pharmaceuticals primarily in Indonesia. The company operates through Pharmaceutical Products, Esthetic, and Toll Manufacturing Services; and Medical Equipments segments. It supplies medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR - extra… Read more